{"preliminary_commentary":{"by_channel":{"x_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"THORA","nct_id":"NCT02041845","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=thora-nct02041845. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"THORA","arms":[{"description":"3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week","label":"A","type":"ACTIVE_COMPARATOR"},{"description":"3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week","label":"B","type":"EXPERIMENTAL"}],"collaborators":["St. Olavs Hospital","Oslo University Hospital","University Hospital of North Norway","Sorlandet Hospital HF"],"completion_date":{"date":"2033-12-31","type":"ESTIMATED"},"conditions":["Small Cell Lung Carcinoma"],"enrollment":{"count":177,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"45 Gy in 30 fractions","otherNames":[],"type":"RADIATION"},{"name":"60 Gy in 40 fractions","otherNames":[],"type":"RADIATION"}],"last_update":"2026-10-14","lead_sponsor":"Norwegian University of Science and Technology","official_title":"A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["NA"],"primary_completion_date":{"date":"2020-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"survival","timeFrame":"2 years"}],"references":[{"citation":"Gronberg BH, Killingberg KT, Flotten O, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7.","pmid":"33662285","type":"RESULT"},{"citation":"Gronberg BH, Killingberg KT, Flotten O, Bjaanaes MM, Brustugun OT, Madebo T, Langer SW, Risumlund SL, Schytte T, Helbekkmo N, Neumann K, Yksnoy O, Engleson J, Fluge S, Naustdal T, Giske LE, Nyman J, Tsakonas G, Halvorsen TO. High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. J Thorac Oncol. 2025 Aug;20(8):1108-1119. doi: 10.1016/j.jtho.2025.04.007. Epub 2025 Apr 19.","pmid":"40258573","type":"DERIVED"},{"citation":"Taranova E, Aanerud M, Halvorsen TO, Killingberg KT, Slaaen M, Gronberg BH. Associations Between Patient-Reported Nutritional Status, Toxicity, and Survival in Limited-Stage SCLC. JTO Clin Res Rep. 2024 Nov 12;6(1):100764. doi: 10.1016/j.jtocrr.2024.100764. eCollection 2025 Jan.","pmid":"39802818","type":"DERIVED"},{"citation":"Killingberg KT, Gronberg BH, Slaaen M, Kirkevold O, Halvorsen TO. Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC. J Thorac Oncol. 2023 Jun;18(6):803-812. doi: 10.1016/j.jtho.2023.01.012. Epub 2023 Jan 27.","pmid":"36716960","type":"DERIVED"},{"citation":"Killingberg KT, Halvorsen TO, Flotten O, Brustugun OT, Langer SW, Nyman J, Hornslien K, Madebo T, Schytte T, Risum S, Tsakonas G, Engleson J, Gronberg BH. Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer. 2022 Apr;166:49-57. doi: 10.1016/j.lungcan.2022.02.002. Epub 2022 Feb 8.","pmid":"35183991","type":"DERIVED"}],"start_date":{"date":"2014-07-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT02041845"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/thora-nct02041845"}